Jongtae Lee
Catholic University of Korea
43 Papers
94 Citations
Jongtae Lee is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 9, co-authored 38 publications. Previous affiliations of Jongtae Lee include New Generation University College & The Catholic University of America.
Chat about Author
Papers
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Su Jin Lee,Jongtae Lee,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Kyoung-Mee Kim,In-Gu Do,In-Gu Do,Sin-Ho Jung,Dong-Seok Yim,Won Ki Kang +12 more
TL;DR: The combination of capecitabine 650 mg/m2 twice daily and everolimus 5 mg twice daily was found to be effective in a small subset of GC patients who were heavily pre-treated.
34
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
Seunghoon Han,Yoo-Jin Kim,Jongtae Lee,Sangil Jeon,Taegon Hong,Gab-jin Park,Jae-Ho Yoon,Seung-Ah Yahng,Seung-Hwan Shin,Sung-Eun Lee,Ki-Seong Eom,Hee-Je Kim,Chang-Ki Min,Seok Lee,Dong-Seok Yim +14 more
TL;DR: It is determined that 5 mg/m2/day is considered to be the most appropriate starting dose for the regimen studied and individualized the maintenance dose for each patient, while minimizing the toxicity using the adaptive approach.
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma
Su Jin Lee,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Won Ki Kang,Jongtae Lee,Dong-Seok Yim,Ho Yeong Lim +8 more
TL;DR: The combination of sorafenib and S-1 showed tolerable toxicity profile and modest clinical efficacy in patients with advanced HCC.
16
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas
Seok Jin Kim,Hye Jin Kang,Jin Seok Kim,Hyeon Seok Eom,Jooryung Huh,Young Hyeh Ko,Jongtae Lee,Dong-Seok Yim,Soo-Youn Lee,Weon Seo Park,Woo Ick Yang,Seung Sook Lee,Cheolwon Suh,Won Seog Kim +13 more
TL;DR: Everolimus (5 mg) can be safely combined with CHOP leading to a feasible and effective regimen for PTCL.
13
On comparison of SAS codes with GLM and MIXED for the crossover studies with QT interval data
Kyungmee Choi,Taegon Hong,Jongtae Lee +2 more
- 01 Dec 2014
TL;DR: This study reviews PROC GLM and PROC MIXED in SAS and compares widely used SAS codes for crossover studies and considers the covariance structure within subject over period which most PK/PD studies and crossover studies ignore.